Recent advances in fluorescent probes for ATP imaging
Talanta,
Journal Year:
2024,
Volume and Issue:
279, P. 126622 - 126622
Published: July 28, 2024
Language: Английский
Nasopharyngeal cancer screening and immunotherapy efficacy evaluation based on plasma separation combined with label-free SERS technology
Ruiying Lin,
No information about this author
Zhengjin Jiang,
No information about this author
Jinyong Lin
No information about this author
et al.
Analytica Chimica Acta,
Journal Year:
2025,
Volume and Issue:
unknown, P. 344070 - 344070
Published: April 1, 2025
Language: Английский
Liquid Biopsy-Derived Tumor Biomarkers for Clinical Applications in Glioblastoma
Bruna Pereira de Lima,
No information about this author
Letícia S. Ferraz,
No information about this author
Sylvie Devalle
No information about this author
et al.
Biomolecules,
Journal Year:
2025,
Volume and Issue:
15(5), P. 658 - 658
Published: May 2, 2025
Glioblastoma
(GBM)
is
the
most
aggressive
primary
brain
tumor
in
adults,
characterized
by
rapid
growth
and
resistance
to
chemotherapy.
Conventional
treatments
remain
largely
ineffective,
with
patient
survival
averaging
around
18
months
after
diagnosis.
Current
diagnostic
methods
rely
on
invasive
tissue
biopsies
imaging
tests.
While
traditional
involve
extracting
samples,
their
routine
use
often
limited
surgical
risks
challenge
of
accessing
sensitive
regions.
Liquid
biopsy
has
emerged
as
a
promising
noninvasive
alternative,
analyzing
circulating
components—such
DNA,
RNA,
extracellular
vesicles,
microRNAs—found
body
fluids.
This
approach
enables
initial
diagnosis
continuous
disease
monitoring,
offering
significant
advantage
over
biopsies,
which
are
impractical
for
frequent
repetition
during
treatment
follow-up.
review
highlights
recent
advances
liquid
biopsy-derived
biomarkers
clinical
management
GBM.
The
discussion
includes
advantages,
limitations,
potential
these
tools
early
monitoring.
A
narrative
literature
published
last
decade
(2014–2024)
was
conducted
using
major
health-focused
scientific
databases.
analysis
focuses
evaluating
relevance
applicability
GBM,
insights
into
its
minimally
effective
tool
improving
glioblastoma
management.
Language: Английский
Systemic toxicity of CAR-T therapy and potential monitoring indicators for toxicity prevention
Jingxian Li,
No information about this author
Huiguang Chen,
No information about this author
Chaoping Xu
No information about this author
et al.
Frontiers in Immunology,
Journal Year:
2024,
Volume and Issue:
15
Published: Aug. 26, 2024
Malignant
tumors
of
the
hematologic
system
have
a
high
degree
malignancy
and
mortality
rates.
Chimeric
antigen
receptor
T
cell
(CAR-T)
therapy
has
become
an
important
option
for
patients
with
relapsed/refractory
tumors,
showing
astonishing
therapeutic
effects
thus,
it
brought
new
hope
to
treatment
malignant
system.
Despite
significant
CAR-T,
its
toxic
reactions,
such
as
Cytokine
Release
Syndrome
(CRS)
Immune
Effector
Cell-Associated
Neurotoxicity
(ICANS),
cannot
be
ignored
since
they
can
cause
damage
multiple
systems,
including
cardiovascular
We
summarize
biomarkers
related
prediction,
diagnosis,
efficacy,
prognosis,
further
exploring
potential
monitoring
indicators
toxicity
prevention.
This
review
aims
CAR-T
on
cardiovascular,
hematologic,
nervous
well
biomarkers,
explore
preventing
toxicity,
thereby
providing
references
clinical
regulation
assessment
effects.
Language: Английский
Winners of the 2023 honor awards for excellence at the annual meeting of the Chinese Medical Association-Taipei: Part III
Peng‐Hui Wang,
No information about this author
Szu‐Ting Yang
No information about this author
Journal of the Chinese Medical Association,
Journal Year:
2024,
Volume and Issue:
87(9), P. 815 - 816
Published: June 25, 2024
Language: Английский
Concordance of HER2 status between primary tumor and circulating tumor cells in breast cancer
Peipei Xie,
No information about this author
Xiaoli Zhang,
No information about this author
Tianyi Liu
No information about this author
et al.
Discover Oncology,
Journal Year:
2024,
Volume and Issue:
15(1)
Published: Dec. 18, 2024
During
tumor
progression,
HER2
expression
undergoes
dynamic
changes.
Circulating
cells
(CTCs)
can
be
used
to
monitor
in
real-time
and
hold
potential
for
clinical
application.
This
study
aimed
evaluate
the
consistency
of
between
primary
tumors
CTCs
patients
with
breast
cancer
(BC).
We
a
previously
established
telomerase
reverse
transcriptase-based
CTC
detection
method
(TBCD)
combined
anti-HER2
antibody
detect
HER2-positive
(HER2
+
CTC)
4
ml
peripheral
blood
from
prior
radiotherapy.
The
results
indicated
that
status
was
inconsistent
histological
results.
Discordance
observed
32.6%
(kappa
value
=
0.325,
p
0.03).
And
among
histologically
HER2-negative
cancer,
rate
32.1%
(9/28).
found
findings.
Further
research
should
explore
significance
detecting
CTCs,
it
is
desired
testing
could
cancer.
Language: Английский
Evaluation and integration of cell-free DNA signatures for detection of lung cancer
Ruyue Xue,
No information about this author
Xiaomin Li,
No information about this author
Lu Yang
No information about this author
et al.
Cancer Letters,
Journal Year:
2024,
Volume and Issue:
604, P. 217216 - 217216
Published: Sept. 3, 2024
Language: Английский
Importance of the CuAAC Reaction in the Synthesis of Platinum Complexes with 1,4-Disubstituted-1H-1,2,3-triazoles: A Review of Their Anticancer Activity
Reactions,
Journal Year:
2024,
Volume and Issue:
5(4), P. 947 - 983
Published: Nov. 24, 2024
Despite
multiple
advances
in
treatment
and
prevention,
cancer
remains
one
of
the
leading
causes
death
worldwide.
Chemotherapy
most
effective
method
for
treatment.
However,
commercial
chemotherapeutic
drugs
have
limited
efficacy,
severe
side
effects,
acquired
resistance.
Therefore,
scientific
community
has
devoted
a
great
effort
to
designing
new,
more
effective,
cheaper
drugs.
In
this
sense,
copper-catalyzed
azide-alkyne
cycloaddition
reactions
(CuAAC)
provide
1,4-disubstituted
1H-1,2,3-triazoles
high
yields
without
forming
by-products.
This
reaction
allows
easy,
efficient,
functional,
ordered,
rapid,
selective,
specific
joining
small
molecules,
giving
rise
complex
molecules.
The
CuACC
simplifies
synthesis
processes,
accelerating
discovery
new
agents
by
allowing
platinum
drugs,
slightly
altering
their
structure,
or
creating
molecules
with
improved
properties.
work
shows
importance
CuAAC
search
metallodrugs
possible
anticancer
activity.
Language: Английский